In the midst of a comprehensive cost cutting program rumored to include thousands of job losses, Teva chief financial officer Eyal Desheh is about to quit, Isra 3 May 2017
While drugmakers tend to gravitate towards the mature markets, they’re also naturally keen to identify investment opportunities elsewhere. After all, sales outs 24 April 2017
With the last set of 2016 financial results of a big-name pharma presented last week, it is possible – when they are viewed in a wider context – to gain some in 10 April 2017
Diabetes has shifted from being a chronic condition that affects a few, to being a global epidemic that is responsible for considerable morbidity and mortality 3 April 2017
The application of cost-effectiveness criteria is a hallmark of the UK’s approach to health technology assessment.differentiating it from many other European co 22 March 2017
For more than a decade, analysts and industry insiders have discussed the potential impact of data in healthcare, but what has actually changed, and what change 7 March 2017
Historically.we have seen combination therapies used to treat illnesses such as malaria.tuberculosis (TB) and AIDS.In all three of these cases.combination thera 27 February 2017
Dr Nicola Davies explores how pharma companies can secure the future of biobetters in the presence of biosimilars and increased payer scrutiny on high prices. 14 February 2017
On November 8, as it gradually became apparent that Donald J Trump was about to defy the expectations of the world to become the 45th President of the United St 6 February 2017
Donald Trump’s warnings on drug prices and the tougher stance being taken by governments in Japan and Europe on paying for medicines make this a worrying time f 30 January 2017
Emily Walsh from the Mesothelioma Cancer Alliance looks at the progress made in the first year of the Cancer Moonshot and considers what lies ahead for the prog 24 January 2017
Dr Nicola Davies explores the market access steps taken by companies such as Takeda to make medicines available and affordable for high priority patient populat 10 January 2017
What more does pharma and biotech know now about the implications of Brexit six months after the UK population voted to leave the European Union? 19 December 2016
A commercial stage biopharmaceutical R&D company, focused on the development of products that address the medical challenges in the therapeutic area of anti-infectives.